Federal health officials have agreed to evaluate Moderna’s innovative influenza vaccine following an unprecedented public confrontation that initially prevented the company from submitting its application for the groundbreaking immunization.
The biotechnology company revealed this development on Wednesday, roughly one week after disclosing that federal vaccine regulators had declined to examine the new immunization, which utilizes Nobel Prize-recognized mRNA science.
The disagreement revolved around a large-scale clinical study involving 40,000 participants that demonstrated Moderna’s innovative vaccine outperformed existing standard flu immunizations in adults aged 50 and above. Federal vaccine oversight director Dr. Vinay Prasad issued an uncommon “refusal to file” notice, criticizing the research for excluding another vaccine brand specifically designed for individuals 65 and older.
Moderna challenged this decision publicly. The company argued that although federal regulators had suggested that particular testing approach, officials eventually approved the study’s framework. Additionally, Moderna provided supplementary comparison information from a different trial that utilized a high-dose immunization for senior citizens. Federal authorities identified no safety issues.
Nevertheless, Moderna announced Wednesday that as part of a settlement, the company will pursue complete authorization for vaccine use in adults between 50 and 64 years old, while seeking expedited approval for those 65 and above, contingent on conducting further research after market release. Company stock prices increased more than 5% following the morning announcement.
Federal regulators are aiming for a decision by August 5th, with Moderna expressing optimism about vaccine availability before year’s end. The company has also submitted approval requests in Europe, Canada, and Australia.
This remarkably public disagreement represents another indication of intensified federal vaccine oversight under Health Secretary Robert F. Kennedy Jr., especially regarding mRNA-based immunizations, which he has previously criticized both before and after assuming the nation’s highest health position.
Over the past year, federal health officials operating under Kennedy’s leadership have withdrawn COVID-19 vaccination recommendations, implemented additional warnings for the two primary COVID vaccines utilizing mRNA technology, and dismissed administration critics from federal advisory committees.
